Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with alopecia areata had a significantly different gut microbiota composition compared to healthy controls, suggesting possible microbiota involvement in the disease's pathogenesis.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study found that elevated beta-hydroxybutyrate levels may worsen the inflammatory immune response in alopecia areata patients and could indicate a poor prognosis with chronic hair loss.

This review discusses the genetics, therapy, and prognosis of childhood alopecia areata, noting that while current treatments are not curative, new modalities may improve future outcomes; it reports no new clinical results.

Dupilumab can both improve and worsen alopecia areata, needing more research.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

This study constructed a model using serum levels of BMP2, CD8A, PRF1, and XCL1 as a non-invasive biomarker to accurately predict recurrence in patients with alopecia areata.

This study found that platelet-rich plasma treatment was an effective and safe option for reducing severity in patients with mild patch-type alopecia areata.

This review highlights that nano-antioxidants show promise as a treatment strategy for immune-mediated inflammatory diseases, like autoimmune and chronic inflammatory conditions, due to their improved stability and targeted delivery, but notes that further research is necessary to optimize their use and assess long-term safety.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

In this study, Brazilian dermatologists reported that patients with alopecia areata, particularly those with severe scalp hair loss, often experience an unmet need for advanced therapies that could improve treatment outcomes beyond the limitations of current options.

This study examined the current clinical practices for diagnosing and managing alopecia areata in Poland, finding that patient care is inadequate and falls short in using validated severity tools and providing access to advanced therapies despite the availability of new medications like Janus kinase inhibitors.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

This study found that human γδTregs promoted hair regrowth and restored hair follicle immune privilege in a model of alopecia areata, suggesting potential for cell-based therapy in autoimmune diseases.

This study investigated alopecia areata in a mouse model, finding that tofacitinib may inhibit disease progression by modulating linoleic acid metabolism and magnesium pathways, particularly affecting CD8+ T cell infiltration in hair follicles, offering insights for potential treatments.

In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

In this animal study, researchers found that local administration of mesenchymal stem cell therapy improved hair regrowth and reduced local inflammatory cytokines in mice with Alopecia Areata, although systemic cytokine levels were unchanged.

This review discusses laser and energy-assisted drug delivery as a treatment for alopecia and concludes that although all studies show positive effects, some reports indicate no superiority over existing monotherapies.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

This review discusses the roles of mesenchymal stem cells in wound healing, particularly their interactions with immune cells, and highlights the potential and current limitations of MSC-based therapies for tissue regeneration.

The researchers reviewed multiple studies and found that baricitinib, a JAK inhibitor, generally improved the condition of patients with severe alopecia areata, with minimal side effects.

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This review discusses the unmet needs and barriers in managing alopecia areata in Latin America, highlighting access constraints and recommending coordinated efforts to improve patient outcomes with promising new treatments.